Treatment of ESBL Infections

Introduction to ESBL Infections

The World Health Organization recommends against using levofloxacin for empiric or definitive treatment of ESBL-producing bacterial infections due to high fluoroquinolone resistance rates (60-93%) among ESBL-positive organisms, which directly translates to treatment failure and increased morbidity and mortality 1, 2
Fluoroquinolone resistance in ESBL-positive E. coli causing infections ranges from 60-93% across different regions, making levofloxacin an unreliable choice that will likely fail 1, 2
Recent fluoroquinolone exposure (within 90 days) is itself a specific risk factor for developing ESBL-producing bacterial infections, creating a vicious cycle where prior use predicts both ESBL presence and fluoroquinolone resistance 2, 3

The Infectious Diseases Society of America recommends carbapenems as the first-line treatment for serious ESBL infections, with Group 2 carbapenems preferred for critically ill patients 6, 7
For ESBL-producing E. coli urinary tract infections with upper tract involvement (pyelonephritis), immediate carbapenem therapy is recommended to prevent progression to sepsis and reduce the treatment failure rate associated with inadequate therapy 6
Piperacillin/tazobactam 4.5g IV every 6 hours (extended infusion) is an acceptable carbapenem-sparing alternative specifically for ESBL-producing E. coli, particularly in hemodynamically stable patients 6, 7
Ceftazidime/avibactam plus metronidazole demonstrates activity against ESBL-producers and represents a newer carbapenem-sparing option for intra-abdominal infections 7

The European Society of Clinical Microbiology and Infectious Diseases recommends oral options for uncomplicated UTIs caused by ESBL organisms, including fosfomycin (3g single dose, may repeat in 3 days), pivmecillinam, or nitrofurantoin, with sensitivity rates exceeding 95% for ESBL-producing Enterobacteriaceae 6

The American College of Emergency Physicians recommends never using levofloxacin empirically when ESBL infection is suspected or confirmed, as the 60-93% resistance rate makes treatment failure highly likely, potentially leading to sepsis progression and increased mortality 1, 2
Fluoroquinolones should be reserved only for patients with confirmed susceptibility on culture results AND documented beta-lactam allergies, not as first-line empiric therapy 6
Cephalosporins (including third-generation agents) are ineffective against ESBL-producers by definition and should not be used even if in vitro testing suggests susceptibility, as ESBL enzymes hydrolyze these agents 6, 7
Delaying appropriate carbapenem therapy in favor of inadequate coverage (like levofloxacin) increases hospital charges significantly and worsens clinical outcomes 6

The World Health Organization notes that in Asia, ESBL carriage rates are highest with the most striking ascending trends, making fluoroquinolone use even more inappropriate in these regions 1, 3
Travelers returning from high-prevalence areas are at significant risk of ESBL colonization, and empiric fluoroquinolone therapy should be avoided in this population 1, 3
Local resistance patterns must guide therapy, but given global fluoroquinolone resistance rates in ESBL organisms, levofloxacin is rarely appropriate regardless of location 7, 8